TS2618768996	drug 0 9	Lapatinib
TS1018768996	drug 28 53	tyrosine kinase inhibitor
TS2318768996	treatedDisease 58 82	metastatic breast cancer
TS4218768996	sideeffect 143 158	adverse effects
TS3918768996	sideeffect 161 187	drug and food interactions
TS3818768996	drug 241 250	lapatinib
TS318768996	treatedDisease 254 278	metastatic breast cancer
TS5318768996	drug 294 303	Lapatinib
TS4118768996	drug 324 349	tyrosine kinase inhibitor
TS2218768996	drugEffect 362 426	targets human epidermal growth factor receptors 1 and 2 ( HER2 )
TS2818768996	drug 450 459	lapatinib
TS2918768996	drug 521 545	tyrosine kinase receptor
TS3318768996	drug 701 710	lapatinib
TS4818768996	drugEffect 724 737	plasma levels
TS4318768996	drug 875 884	lapatinib
TS1518768996	drug 889 901	capecitabine
TS1618768996	drug 962 974	capecitabine
TS1818768996	treatedDisease 1008 1046	HER2-positive metastatic breast cancer
TS3418768996	sideeffect 1047 1074;1092 1098;1106 1137	refractory to anthracycline taxane trastuzumab-containing regimens
TS5718768996	drug 1161 1170	lapatinib
TS5618768996	treatedDisease 1233 1257	metastatic breast cancer
TS5818768996	drug 1406 1415	lapatinib
TS618768996	drug 1420 1432	capecitabine
TS1318768996	sideeffect 1438 1446	diarrhea
TS6118768996	sideeffect 1451 1469	hand-foot syndrome
TS1918768996	drug 1525 1534	lapatinib
TS4718768996	sideeffect 1592 1636	left ventricular ejection fraction decreases
TS1218768996	drug 1686 1695	Lapatinib
TS3718768996	drug 1742 1754	capecitabine
TS4518768996	treatedDisease 1791 1829	HER2-positive metastatic breast cancer
TS2418768996	treatedDisease 1849 1867	metastatic disease
TS2118768996	drug 1977 1986	lapatinib
TS5118768996	drug 1990 2002	capecitabine
TS2018768996	drugEffect 2026 2045	disease progression
R1	treat Arg1:TS1018768996 Arg2:TS2318768996	
R2	treat Arg1:TS2618768996 Arg2:TS2318768996	
R3	treat Arg1:TS3818768996 Arg2:TS318768996	
R4	has_effect Arg1:TS5318768996 Arg2:TS2218768996	
T1	drug 436 447	trastuzumab
T2	drugEffect 480 513	binds to the intracellular domain
R5	has_effect Arg1:TS2818768996 Arg2:T2	
T3	drugEffect 570 614	blockage of the autophosphorylation reaction
R6	has_effect Arg1:TS2918768996 Arg2:T3	
R7	has_effect Arg1:TS2818768996 Arg2:T3	
T4	modeadm 679 683	oral
T7	drug 1147 1158	trastuzumab
R8	treat Arg1:TS5718768996 Arg2:TS5618768996	
R9	has_sideeffect Arg1:TS5818768996 Arg2:TS1318768996	
R10	has_sideeffect Arg1:TS5818768996 Arg2:TS6118768996	
R11	has_sideeffect Arg1:TS618768996 Arg2:TS1318768996	
R12	has_sideeffect Arg1:TS618768996 Arg2:TS6118768996	
T8	sideeffect 1545 1560	cardiac effects
R13	has_sideeffect Arg1:TS1918768996 Arg2:T8	
R14	has_sideeffect Arg1:TS1918768996 Arg2:TS4718768996	
R15	treat Arg1:TS1618768996 Arg2:TS1818768996	
R16	treat Arg1:TS4318768996 Arg2:TS1818768996	
R17	treat Arg1:TS1218768996 Arg2:TS4518768996	
R18	treat Arg1:TS3718768996 Arg2:TS4518768996	
T9	sideeffect 1868 1893;1897 1910;1932 1958	refractory to trastuzumab anthracycline taxane-containing regimens
T5	drugEffect 2063 2088	progression-free survival
R19	has_effect Arg1:TS2118768996 Arg2:TS2018768996	
R20	has_effect Arg1:TS5118768996 Arg2:TS2018768996	
R21	has_effect Arg1:TS2118768996 Arg2:T5	
R22	has_effect Arg1:TS5118768996 Arg2:T5	
